Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Targeting interleukin 23 for Crohn’s disease: finding the right drug for the right patient

Brian Feagan and colleagues1 report in The Lancet the short-term (12 weeks) efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin 23, in patients with moderate-to-severe Crohn’s disease (Crohn’s disease activity index [CDAI] score 220–450) and document endoscopically active mucosal lesions. The study enrolled patients who had previously been exposed to one (93%) or more (79%) tumour necrosis factor (TNF) inhibitors and were receiving corticosteroids (27%) or immunomodulators (26%) with an average disease duration of 13 years.